# Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

> **NCT02012296** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 88 (actual)

## Conditions studied

- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** mifepristone
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT02012296
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-13
- **Primary completion:** 2019-06-10
- **Final completion:** 2020-08-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02012296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02012296, "Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02012296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*